Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. cut its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 4.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 8,034 shares of the biopharmaceutical company’s stock after selling 357 shares during the period. PNC Financial Services Group Inc.’s holdings in Intra-Cellular Therapies were worth $671,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. raised its holdings in Intra-Cellular Therapies by 10.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 22,480 shares of the biopharmaceutical company’s stock valued at $1,878,000 after acquiring an additional 2,157 shares during the last quarter. Barclays PLC increased its holdings in shares of Intra-Cellular Therapies by 282.0% during the 3rd quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company’s stock worth $2,521,000 after buying an additional 25,435 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in shares of Intra-Cellular Therapies by 31.9% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 454,538 shares of the biopharmaceutical company’s stock worth $33,258,000 after buying an additional 109,892 shares during the last quarter. Oak Ridge Investments LLC increased its holdings in shares of Intra-Cellular Therapies by 74.1% during the 4th quarter. Oak Ridge Investments LLC now owns 19,831 shares of the biopharmaceutical company’s stock worth $1,656,000 after buying an additional 8,440 shares during the last quarter. Finally, Cynosure Group LLC increased its holdings in shares of Intra-Cellular Therapies by 161.0% during the 3rd quarter. Cynosure Group LLC now owns 14,442 shares of the biopharmaceutical company’s stock worth $1,057,000 after buying an additional 8,909 shares during the last quarter. 92.33% of the stock is currently owned by institutional investors and hedge funds.

Intra-Cellular Therapies Price Performance

NASDAQ:ITCI opened at $131.45 on Wednesday. The firm has a 50-day moving average of $125.91 and a two-hundred day moving average of $96.52. The stock has a market cap of $13.98 billion, a P/E ratio of -151.09 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a 1-year low of $63.87 and a 1-year high of $131.48.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). The firm had revenue of $199.22 million during the quarter, compared to analysts’ expectations of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. As a group, equities analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Cantor Fitzgerald upgraded Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 14th. Baird R W downgraded Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Piper Sandler restated a “neutral” rating and set a $132.00 price objective (up from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Mizuho downgraded Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $140.00 to $132.00 in a report on Monday, February 24th. Finally, StockNews.com started coverage on shares of Intra-Cellular Therapies in a research report on Wednesday, March 12th. They set a “hold” rating for the company. Ten analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Intra-Cellular Therapies has a consensus rating of “Hold” and an average price target of $106.08.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.